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Phosphorothioate homo-oligodeoxynucleotides were found to be potent inhibitors of herpes lvus
type 2 (HSV-2) but less potent for HSV-1 in cell culture studies. Oligomers with longer chain lengths were more
active against HSV-2 than those with shorter ones. Of all the compounds examined, the 28-mer phosphorothio-
ate homo-oligodeoxynucleotides were the strongest inhibitors of HSV-2. The degree of inhibition was relited to
the base moiety on the order of deoxycytidiie = thymidine > deoxyadenosine. The inhibition of HSV-2 growth
by S-dC23 was dose dependent with a 90% inhibitory dose of 1 FLM. At 50 FM, S-dC2 inhibited HeLa S3 cell
growth by less than 10%. The anti-HSV-2 activity was time and schedule dependent. The oligomer wu most
inhibitory to viral growth when present during the 1-h viral adso*ption period, and this effect could -be
enhanced by continuous drug exposure after the adsorption period. S-dC23 was also an effective inhibitor oftwo
HSV-2 drug-resistant mutants: a phosphonoformate-reistant mutant that induces an altered DNA polymerase
and a 9-(1,3-dihydroxy-2-propoxymethyl)guanine-resistant mutant that does not induce the viral thymidine
kinase. In drug combination studies, phosphonoformate was shown to potentiate the action of S4C2 against
HSV-2 growth. In condusion, because of their potency and selectivity, phosphorothioate homo-oligedeoxynu-
cleotides are a promising new class of anti-HSV agents.
Herpes simplex is one of the common viral infections in
humans (23). A viral type-specific DNA polymerase is.in-
duced in host cells upon herpes simplex virus (HSV) infec-
tion; this enzyme is essential for viral replication, and its
properties are different from those of host DNA polymerases
(1). It is, therefore, a logical target for the development of
selective antiviral compounds (1). Three groups of antilier-
petic compounds that target the viral DNA polymerase have
been developed. Group one consists of various nucleoside
analogs such as 9-(2-hydroxymethyl)guanine (ACV) and
9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), which
are selectively phosphorylated in the infected cells by the
virus-induced thymidine kinase; then their triphosphate
forms compete with dGTP. The viral DNA polymerase
incorporates these triphosphates preferentially compared
with the host DNA polymerases (3, 6, 9). Group two consists
of aphidicolin and its derivatives. These compounds inter-
fere with the ability of deoxynucleoside triphosphates to
bind to the viral DNA polymerase. Their mode of inhibition
of the viral enzyme is different from that of host DNA
polymerase a (7, 15). Group three is composed of the
pyrophosphate analogs such as phosphonoformate (PFA),
which inhibits the release of pyrophosphate (5, 10, 16). A
new group. of compounds. such as oligonucleotide analogs
that could interfere with the binding of the DNA template to
HSV DNA polymerase has been reported (8); these com-
pounds are potential candidates for a new group of anti-HSV
compounds. However, their biological activities in cell cul-
ture have not yet been explored. This report provides
information about the anti-HSV action of phosphorothioate
oligonucleotides in cell cultures.
Recently, phosphorothioate oligodeoxynucleotides were
studied as agents that could potentially control specific gene
* Corresponding author.
expression by. interfering with mRNA function (18). These
compounds were also resistant to the action of nucleases
(18). Studies by Matsukura et al. and Majumdar et al. (12, 13)
demonstrate that phosphorothioate homo-oligodeoxynucle-
otides (S-oligomers) can protect uninfected cells from human
immunodeficiency virus (HIV) infection. However, these
compounds do not inhibit HIV gag. protein expression in
chronically infected cells (13). A possible mechanism for
non-sequence-specific anti-HIV activity may be the inhibi-
tion of HIV reverse transcriptase by competition with the
RNA template (12). In view of the interaction of these
compounds with HIV reverse transcriptase, we examined
their actions on HSV DNA polymerase. S-oligomers are
potent inhibitors of HSV-2 DNA polymerase and its associ-
ated exonuclease by competing with the DNA template for
binding to the enzyme (8). The inhibition of human DNA
polymerases a, j and y, as well as that of HSV-1 DNA
polymerase, was less than that for HSV-2 polymerase (8).
I This finding encouraged us to explore the biological activity
of this new class of compounds on HSV-2 replication.
This paper presents the results of studies from the antiviral
activity of phosphorothioate homo-oligodeoxynucleotides in
cell culture. The mode of inhibition of viral growth, the
spectrum of activity against mutants resistant to other anti-
viral drugs, and the interaction of S-oligomers with other
antiviral drugs are also described.
MATERIALS AND METHODS
Materials. All chemicals used were reagent grade. DHPG
was a gift from Syntex, Inc., Palo Alto, Calif.; PEA was
generously provided by Astra Laboratories, Soderetalje,
Sweden. All S-oligomers and their oxygen congeners were
synthesized and purified as described previously (17, 19).
RPMI 1640 medium was purchased from Hazleton Research
Products, Lenexa, Kans. Fetal bovine serum was obtained
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TABLE 1. Effect of S-oligomers on HSV growtha
HSV plaque formation
HSV strain and Dose No.
S-oligomer (pLM) No. Sizeb
25 PFU/well 250 PFU/well
HSV-2 (333)
Control 0 25 + 5 >100 ++
S-dC7 10 24 ± 2 >100 ++
S-dC15 10 22 ± 7 >100 +
S-dC21 10 0 0
S-dC28 10 0 0
S-dT21 10 11 ± 6 >100 +
S-dT28 10 0 0
S-dA21 10 25 ± 1 >100 +
HSV-1 (KOS)
Control 0 54 ± 5 >100 ++
S-dC28 10 50 ± 4 >100 +
20 59 ± 6 >100 +
S-dT28 10 57 ± 2 >100 +
20 51±2 >100 +
a HSV growth was determined by the plaque reduction assay, as described
in Materials and Methods. The virus was seeded at two dilutions (25 and 250
PFU per well) in the presence of S-oligomer. The data represent the average
numbers of plaques formed in duplicate cultures.
b ++, Sizes of plaques formed were similar to those of the control (no
S-oligomer); +, sizes of plaques formed were smaller than those of the
control.
from Flow Laboratories, Inc., McLean, Va., and kanamycin
was obtained from Sigma Chemical Co., St. Louis, Mo.
Cells and viruses. HeLa S3, HeLa Bu, and Vero cells were
grown and maintained by using established methods (11).
HSV-2 (strain 333), HSV-1 (strain KOS) and all mutants
were maintained as described by Cheng et al. (2). DNA
polymerase mutants (HSV-2 PFAr) were isolated as previ-
ously described (4) except that the parental virus in this case
was HSV-2 (strain 333). Thymidine kinase mutants (HSV-2
TK-) were isolated as indicated previously (4), except that
strain 333 was used and that two passages of plaque purifi-
cation were performed in the presence of 10 ,uM DHPG. The
cytotoxicity study was performed by exposing HeLa S3 cells
to S-oligomers in normal growth medium for 72 h at 37°C, at
which time viable (trypan blue-excluding) cells were counted
and compared with controls (no drug added).
Plaque reduction assays. Vero cells were plated in 24-well
tissue culture plates at a density of approximately 4 x 105
cells per well (2 cm2).'Virus was added at two dilutions (25
and 250 PFU per well) in the presence or absence of drugs in
a total volume of 100 p.1 per well. After a 1-h adsorption
period at 37°C, an overlay containing 1% methylcellulose,
2% fetal bovine serum, and the drug in RPMI medium was
added. After incubation for 48 h, the methylcellulose overlay
was removed and the cells were stained with 0.8% crystal
violet in 50% ethanol.
Virus yield assays. HeLa S3 cells were seeded into 24-well
tissue culture plates in RPMI medium supplemented with 2%
dialyzed fetal bovine serum. The cells were incubated for 24
h at 37°C in the presence or absence of S-oligomers before
viral infection'. The medium was removed, and the cells at a
density of approximately 2.4 x 1 cells per 2-cm2 well were
infected with HSV at a multiplicity of 3 PFU per cell in the
presence or absence of S-oligomers. After a 1-h adsorption
period at 37°C, the virus-containing medium was removed
and the cells were rinsed once with phosphate-buffered
saline and incubated in fresh complete growth medium with
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FIG. 1. Effect of 28-mer S-oligomers on HSV-2 growth. The
inhibition of viral growth was examined by the virus yield assay
described in Materials and Methods. HSV-2 was seeded at a
multiplicity of 3 PFU per cell. The control (no drug added) value was
9.1 x 106 PFU/ml. The percent inhibition of control was calculated.
Data represent the means + standard deviations from three exper-
iments with duplicates in each experiment.
plates were stored at -70°C until the
performed as previously described (11)
stead of CV-1 cells.
viral titration was
by using Vero in-
RESULTS
Effects of S-oligomers on HSV growth. The effect of S-
oligomers on HSV-2 growth was evaluated by using a plaque
reduction assay. In order to determine which compounds
were the most effective, S-oligomers with different chain
lengths and base moieties were used. The antiviral activity of
certain S-oligomers, but not that of their normal oxygen
congeners (data not shown), was evident (Table 1). The viral
inhibition depended on base moiety, with the order of
potency being deoxycytidine = thymidine > deoxyadeno-
sine for 21-mers (Table 1), and on the oligomer chain length.
Longer oligomers were more potent inhibitors than shorter
ones (Table 1). For example, S-dC7 at 10 p.M showed no
inhibition, whereas S-dC28 at the same concentration inhib-
ited HSV-2 growth by 100%. Of all the compounds exam-
ined, S-dC28, S-dT28, and S-d(CT)28 were the most potent
inhibitors of HSV-2 growth (Table 1). However, S-dC28 and
S-dT28 at 20 p.M reduced only the size of the HSV-1 plaques
but not the number of plaques (Table 1).
The 28-mer S-oligomers inhibited HSV-2 growth in a
dose-dependent manner, as determined by a virus yield
assay (Fig. 1). S-dC28 and S-dT28 inhibited 90% of the viral
growth at 1 p.M, whereas 150 p.M PFA was required to
obtain a similar effect under similar assay conditions (see
Table 4). The cytotoxic effect of S-dC28 was also examined
in HeLa cells. After a 72-h exposure to 10 p.M S-dC28, there
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TABLE 2. Effect of S-dC28 on the growth of human
HeLa S3 cellsa
Cell no. (106) at:
S-dC28 (>LM) Oh 72 h (mean ± SD,0h ~~~~~n=4)
0 0.2 1.5 ± 0.2
3 0.2 1.6 + 0.1
10 0.2 1.7 ± 0.4
50 0.2 1.4 ± 0.5
a Cells were grown under the conditions described in Materials and
Methods. Data represent the number of cells per well at 0 and 72 h after the
addition of S-dC28.
was no apparent cytotoxicity, and even at 50 ,uM, only 7%
growth inhibition was observed (Table 2).
Schedule dependence of the anti-HSV-2 action of the 28-mer
S-oligomers. The 28-mer S-oligomers [S-dC28, S-dT28, and
S-d(CT)28] were added to the cells at 10 ,uM before, during,
or after the 1-h viral adsorption period. After 24 h of
incubation, the titers of the virus were determined. When the
S-oligomers were present during the 1-h viral adsorption
period, 90% inhibition of the viral growth was observed (Fig.
2a); however, further enhancement of the antiviral action
was observed when the cells were continuously exposed to
the S-oligomers (Fig. 2b). In contrast, preinfection or post-
infection incubation alone resulted in no significant decrease
in virus titers (Fig. 2a).
Combination effect of S-oligomers with PFA or DHPG on
HSV-2 growth. Since different antiherpes compounds pos-
sess different mechanisms to inhibit viral DNA polymerase,
the combination of PFA or DHPG with S-dC28 was exam-
ined. HSV-2-infected HeLa cells were exposed to S-dC28 at
various concentrations in the presence of either PFA (50
,uM) or DHPG (2 ,uM). After a 24-h drug exposure, the virus
titer was determined. PFA (50 ,uM), but not DHPG (2 ,uM),
potentiated the anti-HSV-2 action of S-dC28 at 0.5, 1, and 3
p,M (Table 3).
Effect of S-dC2 on drug-resistant HSV-2 mutants. HSV-2
(strain 333) mutants resistant to DHPG or PFA were devel-
oped in this laboratory, and their subclones DHPGra and
PFAr1la were chosen for this study. The 90% inhibitory dose
(ID90) of DHPG for DHPGr was 215 ,uM, and that for the
parental strain was 3.8 ,uM (Table 4). An enzyme study
showed that this mutant does not induce viral thymidine
kinase activity but does induce viral DNA polymerase and
DNase activities, as does its parental strain (data not
shown). The lack of thymidine kinase activity, and conse-
quently the lack of DHPG triphosphate formation, could be
one explanation for DHPG resistance. This mutant was as
sensitive to S-dC28 as was its parental strain, and 0.5 ,uM
S-dC28 inhibited viral growth by 75% (Table 4).
The PFAria mutant had an ID90 of 1.7 mM to PFA, which
was 11-fold higher than that of parental strain 333 (ID90 of
0.15 mM; Table 4). This mutant induced an altered viral
DNA polymerase that is less sensitive to PFA but still
sensitive to S-dC28 (data not shown). In the presence of 0.5
,uM S-dC28, PFArla viral growth was inhibited by 90% (Table
4).
DISCUSSION
The results presented here demonstrate that S-oligomers
are a group of potent selective inhibitors of HSV-2 growth in






























FIG. 2. Effect of drug scheduling on HSV-2 growth. HSV-2
growth was examined by using the virus yield assay. HeLa S3 cells
were infected at a multiplicity of 3 PFU per cell, and 10 ,uM
S-oligomer was added as indicated. (a) Cells were incubated with
S-oligomer for 1 h during a 1-h virus adsorption period (A), for 24 h
after the virus adsorption period (B), and for 24 h before and after
(but not during) the virus adsorption period (C). (b) Cells were
incubated with S-oligomer for 1 h during the virus adsorption period
(A) and further incubated with the drug for 24 h after the adsorption
period (D). Titers of the virus were determined by using the plaque
reduction assay described in Materials and Methods. The control
(no drug added) value was 4.5 x 106 PFU/ml. Data represent the
means ± the standard deviations of percent virus growth of the
control of at least two experiments with duplicates in each experi-
ment.
could be at least two different mechanisms of action for their
antiviral activity: inhibition of the viral DNA polymerase
and interference of the viral adsorption or penetration.
Our results suggest a correlation between the inhibition of
viral DNA polymerase (8) and the inhibition ofHSV growth.
S-oligomers inhibited HSV-2 DNA polymerase better than
HSV-1 DNA polymerase (8); these compounds also inhib-
ited HSV-2 growth better than HSV-1 growth in cell culture
studies (Table 1). Longer S-oligomers were more potent
inhibitors than shorter ones. This was observed in both viral
enzyme (8) and viral growth studies (Table 1). However,
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TABLE 3. Effect of the combination of S-dC28 with DHPG
(2 FM) or PFA (50 ,uM) on HSV-2 growtha
% of control (mean ± SD) with S-dC2S at (>M):
Agent
0 0.5 1 3
Control 100 ± 14.0 45.9 ± 13.3 8.3 ± 2.4 3.0 ± 1.3
DHPG 100 ± 10.9 42.3 ± 11.4 6.9 ± 0.6 3.4 ± 0.6
PFA 100 ± 15.6 13.2 ± 1.0 3.6 ± 0.4 1.6 ± 0.04
a HeLa cells were exposed to HSV-2 at a multiplicity of 3 PFU per cell for
1 h in the presence or absence of S-dC28. The medium was removed, and fresh
medium that contained the anti-HSV agents DHPG (2 FM) or PFA (50 ,uM)
plus S-dC28 at the indicated concentrations was added. The control (no drug
added) values ranged from S x 106 to 7 x 106 PFU/ml. The virus yield in the
presence of either DHPG or PFA alone was 17.5% + 1.9%o or 50%o ± 7.8% of
the control yield, respectively. Data represent the mean (± the standard
deviation) percentages of the control of three determinations.
their oxygen congeners do not appear to inhibit viral DNA
polymerase (8) or affect viral growth (data not shown). In
addition, this study shows a dose-dependent inhibition of
HSV-2 growth with an ID90 of 1 ,uM, which correlates well
with the observed inhibition of viral DNA polymerase (Ki
value of 7 nM). These results suggest that the anti-HSV-2
action of S-oligomers could be partially mediated through
the inhibition of viral DNA polymerase.
Second, although there is a good correlation between
antiviral activity of S-oligomers in cell culture and the
inhibition of HSV-2 DNA polymerase, the mechanism of
action may also involve an interaction between these com-
pounds, the virus, and cells since the most effective period
for S-oligomer activity was during the 1-h viral adsorption
period (Fig. 2). Recent studies by Wudunn and Spear suggest
that heparan sulfate on the cell surface can serve as the
initial receptor for HSV infection (24). Glycosaminoglycan
heparin with a sulfated polyanionic carbohydrate structure
can block HSV binding (14, 20) by interacting with certain
glycoproteins on the surface of the viral envelope (24). Since
S-oligomers also have a polyanionic structure, it is possible
that S-oligomers may interact directly with these glycopro-
teins on the HSV envelope through the phosphorothioate
backbone. Alternatively, the interaction could also occur
between S-oligomers and the proteins at the plasma mem-
brane. Therefore, viral adsorption or penetration could be
altered. Furthermore, the binding of S-oligomers to the
virion or the process of infection itself could also cause an
increased cellular uptake of these compounds. This hypoth-
esis is based on the fact that continuous exposure of S-
TABLE 4. Susceptibility of HSV-2 and its mutants
to herpetic inhibitors
Virus growth
(% of control) ID90 (>M)
Strain with S-dC28 at (PM)a:
0.5 1.0 DHPG PFA
333 45 13 8 2 3.8 150
DHPGrb 24 18 2 1 215 NDC
PFArd 10 5 3 1 ND 1,700
a HeLa S3 cells were infected with HSV-2 at a multiplicity of 3 PFU per
cell, and virus growth was examined by using the virus yield assay. Data
represent the mean (± the standard deviation) percentages of virus growth of
the control (no drug added) of three experiments with duplicates in each
experiment. The control values ranged from 4 x 106 to 10 x 106 PFU/ml.
b Thymidine kinase mutant of HSV-2 that is resistant to DHPG.
c ND, Not determined.
d DNA polymerase mutant of HSV-2 that is resistant to PFA.
oligomers enhanced the anti-HSV-2 effect, whereas drug
exposure after infection for 24 h alone did not have any
effect. The increased uptake of S-oligomers through the viral
infection process could allow the compounds to inhibit viral
DNA replication by inhibiting viral DNA polymerase. We do
not rule out the possibility that the enhancement of the
antiviral effect could be due to the interruption of virus
adsorption or penetration because the washing procedure
may have not been sufficient for removing all of the inocu-
lated virus. However, our results do not support this possi-
bility. First, in contrast to continuous exposure, exposure to
S-oligomers only after viral adsorption did not show any
effect on HSV-2 growth (Fig. 2a, exposure protocol B).
Furthermore, in our unpublished studies, the inhibition of
[14C]thymidine-labeled HSV-2 virion uptake did not parallel
inhibition of the virus yield. The latter was more sensitive to
S-dC28 compared with the former. These data suggested that
the blocking of HSV-2 adsorption or penetration was not
accountable for the sole mechanism of action. The detailed
mechanism of the anti-HSV action of S-oligomers is cur-
rently under investigation.
The reason why HSV-2 is more susceptible to S-oligomers
than HSV-1 is unclear. On the basis of previous studies,
however, there are two possible explanations for this obser-
vation. First, S-dC28 has been shown to inhibit HSV-2 DNA
polymerase more strongly than HSV-1 DNA polymerase (8).
Thus, differences in the susceptibility of the enzymes to
inhibition by these compounds could affect viral DNA
replication and result in differences in inhibition of the virus
growth. Second, differences in drug uptake in HSV-infected
cells could also play a role. Previous studies by other
investigators suggest that there may be two different types of
cell surface receptors or pathways for the entry of HSV-1
and HSV-2 into cells (21, 22). Our unpublished observations
suggest that the cellular uptake of these compounds could be
enhanced by HSV-2 infection but not by HSV-1. This could
also contribute to the differences between HSV-1 and HSV-2
in their susceptibilities to these compounds. A further ex-
planation of these differences will require knowledge of the
molecular details involved in initial and subsequent interac-
tions of the virion and the cell.
In summary, S-oligomers are a group of new compounds
active against HSV-2 growth at micromolar concentrations
in cell culture. Their potency is comparable to those of
DHPG and ACV (data not shown). In addition, HSV-2
mutants that exhibit decreased susceptibilities to PFA or
DHPG are still susceptible to S-oligomers. These results
suggest that S-oligomers potentially represent a new class of
anti-HSV agents.
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